MedPath

Exercise Capacity in Congenital Heart Disease: The Role of Muscle Metabolism

Completed
Conditions
congenital heart disease
decreased exercise tolerance
10010394
Registration Number
NL-OMON45601
Lead Sponsor
niversitair Medisch Centrum Groningen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Patients with pulmonary arterial hypertension:
- Between 8 and 18 years of age
- Diagnosis confirmed at the UMC Groningen
Patients with a Fontan circulation:
- Between 8 and 18 years of age
- Diagnosis confirmed by the UMC Groningen
- Successfully undergone a Fontan procedure
- Stable haemodynamic condition
Patients with tetralogy of Fallot:
- Between 8 and 18 years of age
- Diagnosis confirmed by the UMC Groningen
- Successfully undergone procedure to repair the abnormalities;Healthy subjects between 8 and 18 years of age, without significant cardiac defect or known comorbidity affecting exercise tolerance.;All parents and subjects from 12 y.a.o.:
Written informed consent

Exclusion Criteria

Patients and controls:
- age <8 and >18
- not familiar with the Dutch language
- ineligible to perform an exercise test
- with contra-indications for 31P/1H MRS examination
- (suspected) pregnancy
- mental retardation
- with comorbidity affecting exercise tolerance (Anaemia, musculoskeletal injury)
- being under examination for non-diagnosed disease at the time of investigation
Patients:
- with severe complications due to cardiomyopathy/arrhythmia
- with exacerbation of disease at time of investigation
- with a pacemaker implanted
- with severe complications due to epilepsy
- with musculoskeletal disease (i.e. muscular dystrophy)

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>o Quadriceps phosphocreatine concentration (PCr) at rest and during progressive<br /><br>exercise (exercise intensities 0-100% of workload corresponding to VO2max)<br /><br>o Quadriceps inorganic phosphorus concentration (Pi) at rest and during<br /><br>exercise (exercise intensities 0-100% of workload corresponding to VO2max)<br /><br>o Quadriceps pH at rest and during exercise (exercise intensities 0-100% of<br /><br>workload corresponding to VO2max)<br /><br>o Post-exercise recovery rate of quadriceps PCr concentration<br /><br>o Post-exercise recovery rate of quadriceps Pi concentration<br /><br>o Post-exercise recovery rate of quadriceps pH</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>n.a.</p><br>
© Copyright 2025. All Rights Reserved by MedPath